New treatments such as ado-trastuzumab emtansine (Kadcyla), fam-trastuzumab deruxtecan-nxki (Enhertu), and CDK4 / 6 inhibitors revolutionize treatment across breast cancer subtypes, according to Gregory Vidal, MD,...
The addition of tucatinib to the maintenance of standard of care in the first-line setting of patients with HER2-positive metastatic breast cancer will be considered in...
Recent Comments